NCT01786265View on ClinicalTrials.gov

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

February 5, 2013

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions
Prostate AdenocarcinomaRecurrent Prostate Carcinoma
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Bicalutamide

Given PO

DRUG

Degarelix

Given via injection

DRUG

Flutamide

Given PO

DRUG

Goserelin Acetate

Given via injection

DRUG

Leuprolide Acetate

Given via injection

DRUG

Nilutamide

Given PO

DRUG

Prednisone

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01786265 - Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter